NIDA | Technology Transfer

Novel Opotically Active Dopamine D3 Receptor Selective Agonists

Read more about Novel Opotically Active Dopamine D3 Receptor Selective Agonists

European Patent
20724970.7
Filed on 2020-04-13

D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF

Read more about D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF

Canada
3136151
Filed on 2020-04-13

Novel Opotically Active Dopamine D3 Receptor Selective Agonists

Read more about Novel Opotically Active Dopamine D3 Receptor Selective Agonists

Australia
2020270992
Filed on 2020-04-13

FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE

Read more about FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE

Patent Cooperation Treaty
PCT/US2021/013300
Filed on 2021-01-13

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Turkey
17711971.6
Filed on 2018-09-11

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Slovakia
17711971.6
Filed on 2018-09-11

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Slovenia
17711971.6
Filed on 2018-09-11

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Sweden
17711971.6
Filed on 2018-09-11

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Serbia
17711971.6
Filed on 2018-09-11

Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Read more about Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders

Romania
17711971.6
Filed on 2018-09-11

Subscribe to NIDA